https://www.selleckchem.com/pr....oducts/actinomycin-d
We performed this first-in-human efficacy trial of Takeda's bivalent norovirus vaccine candidate (TAK-214) against moderate or severe acute gastroenteritis (AGE) in healthy adults. This double-blind, randomized, placebo-controlled phase 2b trial was conducted over two winter seasons in 18-49year-old US Navy recruits. Participants were randomized (11) to receive intramuscular injections of saline placebo (N=2,357) or TAK-214 [15μg GI.1 and 50μg GII.4c VLPs, 0.5mg Al(OH) ] (N=2,355), and monitored for 45days post-vaccination for AGE
Like
Comment
Share
